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Abstract
Data generated by the numerous clinical trials conducted annually worldwide have the potential to be extremely
beneficial to the scientific and patient communities. This potential is well recognized and efforts are being made to
encourage the release of raw patient-level data from these trials to the public. The issue of sharing clinical trial data
has recently gained attention, with many agreeing that this type of data should be made available for research in a
timely manner. The availability of clinical trial data is most important for study reproducibility, meta-analyses, and
improvement of study design. There is much discussion in the community over key data sharing issues, including
the risks this practice holds. However, one aspect that remains to be adequately addressed is that of the accessibility,
quality, and usability of the data being shared. Herein, experiences with the two current major platforms used to store
and disseminate clinical trial data are described, discussing the issues encountered and suggesting possible solutions.
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Background
Approximately 30,000 clinical trials are conducted an-
nually worldwide, producing a large volume of raw
patient-level data. Sharing of such data would allow
the scientific community to independently verify pub-
lished results and evaluate new hypotheses, either by
extending the analysis of data from a clinical trial or by
combining data from different trials. The unavailability
of original research data is a known and significant bar-
rier to reproducibility. Further, the enormous quantity
of raw, individual-level clinical and high-throughput
mechanistic assay data available should function as a
springboard for scientific advances and development of
new techniques in clinical informatics. With this in
mind, recent market and regulatory forces have been
driving initiatives to release such data to the public.
Nevertheless, for this potential to be realized, the data
have to be accessible and usable.
Many government agencies, research groups, and
pharmaceutical companies have begun implementing
mechanisms for data sharing [1]. While there is ongoing
discussion in the community over the key issues and
risks of sharing data [2], most sharing of clinical trial
data by pharmaceutical companies is currently per-
formed on a voluntary basis through web-based portals
where access is carefully controlled. Whether this volun-
tary, controlled sharing will be sufficient to meet the
goals of transparency and reanalysis is yet to be assessed.
One aspect that has not been thoroughly addressed is
that of the accessibility, quality, and usability of the data
being shared. From our experiences in seeking access to
patient-level clinical trial data through the two current
major platforms used to store and disseminate these data,
the process is still very cumbersome and lengthy and,
when data are provided, they are not readily useable.
Our experience in the pursuit of open clinical
trial data
One of the largest of such platforms is ClinicalStudy
DataRequest.com, which, to date, allows users to
browse over 2,100 clinical trials sponsored by 12 dif-
ferent pharmaceutical entities, select those of interest
and, following the platform’s protocol, request access
to the data [3]. However, the process of gaining access to
the data is time consuming and demotivating. A detailed
research proposal providing a lay summary, study design,
primary and secondary endpoints, statistical analysis plan,
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and publication plan needs to be provided. The submitted
proposal is reviewed by an independent research panel
which decides whether to approve the request for data.
This requirement for review prior to allowing data access
is considered necessary to ensure that data are released
only to responsible and qualified parties, thus avoiding
misinterpretation of the data and publication of mislead-
ing, erroneous results. Once approved, a data-sharing
agreement is sent to all trial sponsors and returned to the
requesting researcher for signature. Following sign-off,
trial sponsors prepare, anonymize, and make the data
available via an analysis platform. Thus, the original data
are never actually shared with the researcher and analysis
is limited to that which can be conducted via the
platform.
Four proposals, each requesting data for different re-
search questions and from different trials, two of which
combined data from several sponsors, were submitted to
ClinicalStudyDataRequest.com (from December 2014 to
January 2015). Each submission was followed by numer-
ous exchanges of correspondence asking for additional
information not initially requested, such as the resume
of the team’s statistician or confirmation of intent to
conduct the analysis within the data access system,
resulting in a processing time of over 2 months from
submission to approval or rejection. At the time of writ-
ing, over 5 months after initial submission, two requests
were still pending their data-sharing agreement, one had
been denied and was pending re-submission, and the
fourth was still waiting to receive access to data (the
timeframes are illustrated in Fig. 1). While every step in
this process could be argued to be necessary to prevent
misuse and protect patient privacy, our experience from
four attempts to obtain data through the site has led us
to conclude that the process is less than ideal and would
benefit from improved efficiencies to better foster
advances in research, while minimizing the inherent
risks of data sharing.
Faster data acquisition, within days, was achieved via
the Project Data Sphere database (projectdatasphere.org)
which stores, shares, and allows analysis of patient level
phase III cancer trial data [4]. The database currently
holds information from over 50 cancer clinical trials
and, after registration and submission of a simple re-
search proposal, which was swiftly approved, all data on
the site were made available for either download or ana-
lysis on an online SAS platform. Nevertheless, whilst
obtaining the data was fast and relatively straightfor-
ward, other than when using the restrictive online tools,
the data were not readily usable. For the studies available
on the site, data schemas were not uniform, making in-
tegration and comparison of data from different studies,
such as meta-analyses, difficult. Further, table and vari-
able names were uninformative. Long annotation files
had to be manually read to assess what data were available
and, for at least five studies, no annotation files were pro-
vided. Of even greater concern was the fact that only data
pertaining to the control, placebo, or comparator arms
were made available, making the possibility of reanalysis
of studies, such as those which failed, impossible.
While this is merely the dawn of a new age of open
clinical trial data and, understandably, hurdles toward
implementation of safe and efficient clinical trial data-
sharing platforms are expected, examples of effective
Fig. 1 Timelines for data request research proposals submitted to ClinicalStudyDataRequest.com. Four research proposals were submitted to the
site requesting access to data in different medical areas. Each box represents a different stage in the proposal evaluation and granting of access
to data. IRP, Independent research panel
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platforms already exist. One initiative, led by the National
Institute of Allergy and Infectious Diseases, is the
Immunology Database and Analysis Portal (ImmPort;
www.immport.org) data-sharing platform [5]. In the
short time since its implementation, over 140 datasets
(including 36 clinical trials, as of October 2015) from
various research consortia were made publicly avail-
able in an easily accessible and readily useable way.
Access to the data stored in ImmPort, most of which
is parsed, annotated and structured, is made available
immediately after registration to the site. With hun-
dreds of downloads per month, ImmPort is an im-
portant source of raw data and protocols from
clinical trials, mechanistic studies, and novel methods
for cellular and molecular measurements.
Our experiences, albeit based on a small sample, have
led us to the conclusion that, although the pharmaceut-
ical industry is making some effort, it is not yet highly
motivated to share clinical trial data in a timely manner.
Clinical trial data are complex and comprise multiple as-
pects; a widespread adoption of standards for publishing
and sharing such data would prevent many of the issues
we encountered. The recently published Institute of
Medicine’s report [1] provides guidelines for clinical trial
data sharing. Adoption of these guidelines, along with
standards for data representation, such as standard data
table templates and standard vocabularies, would greatly
assist in making open clinical trial data useful to the
community. An agreed-upon protocol for the approval
of data requests and reasonable time frames for the
process would also shorten the path from resource to re-
search. Naturally, newer and acceptable standards should
be developed in collaboration with the industry pro-
viders. We recommend that action be taken to establish
community-wide standards and guidelines and a plat-
form for communication between researchers and pro-
viders regarding data safety, access, and usability
concerns. Additionally, a scheme to increase the indus-
try’s motivation for data sharing, rewarding companies
that make data readily accessible (e.g. by extension of
the duration of patent exclusivity for the tested drug [6]
or by participation in publications related to re-use of
the data) and covering the costs of this process, should
also be considered.
Conclusions
Better sharing of clinical trial data holds great potential
for the scientific and patient communities. Collaborative
establishment of data standards and processes for data
sharing and acquisition would greatly accelerate the pro-
gress of research based on this rich data source.
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